Patents & IP

Crystalline psilocybin — Polymorph A. Covers the specific crystal form used in COMP360.

Scope: Broad WIPO process claims covering synthesis, purification, and specific crystalline form. Critics argue Polymorph A is a trivially modified form of a naturally occurring compound with extensive prior art.

Challenge status: No successful challenge filed as of mid-2026. Multiple researchers have argued prior art (Sandoz 1965; Shulgin documentation) should invalidate.

Pledge status: Compass has indicated no intent to sign a patent pledge (Marks & Cohen, Harvard Law Review, 2022). In 2023 public statements, Compass indicated it would not pursue enforcement against researchers or non-commercial users — but this is not a legally binding commitment.

Patents covering elements of the therapy room environment used during psilocybin sessions — including specific lighting conditions, furniture arrangements, and music playlists.

Scope: Method-of-treatment patents extending IP beyond the molecule to the therapeutic context. If upheld and enforced, could require licence for any supervised psilocybin session using similar environmental elements.

Challenge status: No formal challenge. Widely criticised in literature (Marks & Cohen 2022; Rosenbaum et al.) as improperly broad.

Pledge status: No pledge.

Albert Hofmann and Sandoz isolated and patented psilocybin in 1958/1965. Patent long expired.

Scope: Original isolation patent. Now expired — forms foundational prior art for challenging modern overbroad claims on psilocybin itself.

Challenge status: Not applicable — expired

At least 24 psilocybin patent processes registered globally as of 2023. Additional filings across MDMA, ibogaine, 5-MeO-DMT, DMT, ketamine, and mescaline derivatives.

Scope: Compounds, formulations, delivery methods, therapy protocols, session environments, digital monitoring systems, and biomarker detection. IP is moving upstream (molecules) and downstream (therapy protocols, monitoring apps) simultaneously.

Challenge status: The Open Access Psilocybin Project and similar initiatives are building prior art databases. No successful broad challenge completed as of mid-2026.

IP held across atai subsidiary companies covering ibogaine formulations (DemeRx), R-ketamine (Perception Neuroscience), 5-MeO-DMT delivery (Viridia), and DMT analogs (EntheogeniX). Aggregate portfolio constitutes a multi-compound IP enclosure strategy.

Scope: Portfolio model creates risk of coordinated IP enclosure across multiple compounds simultaneously — single entity or affiliated entities holding IP across the most promising psychedelic compounds.

Challenge status: No consolidated challenge. Individual compound challenges would need to be filed separately.

Pledge status: No pledge. Christian Angermayer (atai co-founder) has publicly opposed non-commercial models.

CYB003 is a deuterium-modified psilocybin analog. Deuterium substitution (replacing hydrogen atoms with deuterium) is a pharmaceutical strategy for modifying metabolism and half-life — and for creating patentable analogs of compounds with expired or challenged patents.

Scope: Specific deuterated molecular structures and their therapeutic use. Strategy specifically designed to create new patent protection on compounds derived from naturally occurring psychedelics.

Challenge status: No challenge filed. Prior art argument is that deuterium modification is a standard pharmaceutical technique (known as 'deuterium switching') — not a novel invention.

Pledge status: No pledge.

TRIPS Article 31 allows compulsory licensing of patented pharmaceuticals for public health emergencies. Multiple countries (Brazil, Thailand, India) used this mechanism for HIV/AIDS antiretrovirals. Psychedelic advocates have argued the same mechanism could apply if psilocybin or MDMA receive FDA approval but are priced out of reach.

Initiative to build prior art database and challenge overbroad psilocybin patents. Key argument: Sandoz 1965 patent, Shulgin documentation, and published scientific literature from 1950s-1970s constitute prior art that should invalidate many modern claims.

• New Compass, atai, MindMed, Cybin, GH Research, or Beckley patent grant or challenge filed
• Any patent pledge or legally binding open-access commitment by a psychedelic sector actor
• Any jurisdiction adopting standardised dosing units or plain packaging requirements for psychedelics
• Any prior art challenge successfully invalidating a psychedelic patent claim
• Any compulsory licensing discussion applied to a psychedelic compound
• Any new therapy protocol or session environment patent filed
• Any new deuterium-switching or analog patent filed on a psychedelic compound

The cumulative patent landscape means that basic psilocybin therapy — a naturally occurring compound used ceremonially for centuries, with documented pharmacological research since the 1950s — is being enclosed behind a private IP portfolio. Compass holds the key process patent (Polymorph A), broad WIPO process claims, and therapy room design patents. atai holds a portfolio across multiple compounds simultaneously. Cybin is using deuterium-switching to create new patent positions on molecular derivatives. The aggregate effect is that multiple vectors of the psychedelic therapeutic pathway — the compound, the session structure, the monitoring technology, the clinical protocol — are being enclosed in parallel.

The MAPS/Lykos situation adds a structural dimension: the FDA rejection of the Lykos MDMA NDA (August 2024) does not affect MAPS/Lykos IP ownership. The non-profit holds IP; the commercial spin-off holds commercialisation rights. This hybrid structure creates mission alignment in theory and commercial pricing pressure in practice — with no legally binding access commitments in the commercial entity.

The critical intervention is prior art challenges — and the window is narrow. Once FDA approval is granted on patented Polymorph A, the patent’s commercial legitimacy is substantially reinforced. The Open Access Psilocybin Project needs resourcing and legal support before approval, not after. Compulsory licensing provisions (TRIPS Article 31) provide a post-approval mechanism but require political will that has not been demonstrated. The IP foreclosure of Tier 2 is not a future risk — it is the current IP landscape applied to a regulatory framework that does not yet exist. (See Tab 6 for how this forecloses specific tiers.)

We store only the name and email you enter here, and use them only to send this digest. Every email carries an unsubscribe link, which removes the address immediately.